https://www.selleckchem.com/products/sw033291.html
In the past decade many novel, and in some cases transformative, cancer medicines have entered the market. Their prices and the amount spent on them by governments have increased rapidly, bringing to the forefront trade-offs that must be made. In this paper we explore the Australian public's attitude towards the funding of high cost cancer medicines (HCCM) to inform reimbursement and health technology assessment (HTA) policy. A survey consisting of 49 questions about the funding of HCCMs was developed by the investigators. Recruitment
Synes godt om
Kommentar
Del
